Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease.
Ming-Han ChenI-Cheng LeeMing-Huang ChenMing-Chih HouChang-Youh TsaiYi-Hsiang HuangPublished in: Annals of the rheumatic diseases (2021)
Not only rituximab, but also abatacept has a high risk of HBV reactivation in patient with RA with RHB. Anti-HBs positivity cannot confer HBV reactivation-free status if the anti-HBs levels are not high enough for patients with RHB on rituximab and abatacept treatment.